Analyst Jason McCarthy from Maxim Group reiterated a Buy rating on Gain Therapeutics (GANX – Research Report) and keeping the price ...

BETHESDA, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the ...

Heron Therapeutics Inc (HRTX) stock saw a modest uptick, ending the day at $2.02 which represents a slight increase of $0.07 or 3.59% from the prior close of $1.95. The stock opened at $1.99 and ...

The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 9.81% of ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.49, moving -0.2% from the previous trading session. This change lagged the S&P 500's 1.7% gain on the day. Elsewhere, the Dow ...

Viking Therapeutics Inc. (NASDAQ: VKTX), a clinical-stage biotechnology company with a market cap approaching $7 billion, is ...

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Sarepta's Elevidys approval, revenue growth projections, and competitive position make it a strong investment in DMD ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...